Chronic everolimus treatment of high‐fat diet mice leads to a reduction in obesity but impaired glucose tolerance

Everolimus, which inhibits mTOR kinase activity and is clinically used in graft rejection treatment, may have a two‐sided influence on metabolic syndrome; its role in obesity and hyperglycemic in animals and humans, however, has been explored insufficiently. This study further determined how continu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Geng‐Ruei, Hou, Po‐Hsun, Wang, Chao‐Min, Wu, Ching‐Feng, Su, Huang‐Kai, Liao, Huei‐Jyuan, Chen, To‐Pang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955951/
https://www.ncbi.nlm.nih.gov/pubmed/33715287
http://dx.doi.org/10.1002/prp2.732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955951/
https://www.ncbi.nlm.nih.gov/pubmed/33715287
http://dx.doi.org/10.1002/prp2.732

Ejemplares similares